Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in South Korea / NCT07447271
Active, not recruiting Not applicable

Ultrasound Guided Cervical Selective Nerve Root Block Versus Fluoroscopic Guided Cervical Transforaminal Epidural Block

NCT07447271 · tracked via the Priya Life Science South Korea tracker
Sponsor
Pusan National University Yangsan Hospital
Phase
Not applicable
Started
2025-12-22
Last updated
2026-03-03

Condition(s) studied

Cervical Radiculopathy

Investigational drug(s) / intervention(s)

ultrasound guided cervical selective nerve root blockfluoroscopy-guided cervical transforaminal epidural block

ultrasound guided cervical selective nerve root block: A patient presenting to the pain clinic with cervical neck pain and upper extremity radicular pain, whose symptoms did not improve with medication, demonstrated a positive Spurling test on physical examination, and showed cervical radiculopathy at the C3/4 to C7/T1 level on imaging studies (CT or MRI), underwent an ultrasound-guided cervical selective nerve root block

fluoroscopy-guided cervical transforaminal epidural block: A patient presenting to the pain clinic with cervical neck pain and upper extremity radicular pain, whose symptoms did not improve with medication, demonstrated a positive Spurling test on physical examination, and showed cervical radiculopathy at the C3/4 to C7/T1 level on imaging studies (CT or MRI), underwent a fluoroscopy-guided cervical transforaminal epidural block

Study summary

This study retrospectively analyzed medical records and imaging records (ultrasound images, fluoroscopy-guided images) of US-CSNRB and FL-CTFEB procedures performed at the Yangsan Pusan National University Hospital Pain Clinic outpatient department from May 1, 2019, to April 30, 2024. It compared the therapeutic effects (pain reduction), procedure-related indicators (comparison of contrast agent spread), safety (incidence of complications), and changes in analgesic usage.

The primary outcome of this study is the difference in pain chage (Visual Analogue Scale, VAS) between patients undergoing US-CSNRB and FL-CTFEB. The secondary outcomes are comparison of contrast agent spread and comparison of procedure-related complication rates.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adult male and female patients aged 18 years or older. * Patients diagnosed with cervical radiculopathy who underwent US-guided or FL-guided procedures. * Patients with clearly documented pain scale (VAS) assessments in medical records at the following time points: 1st visit (before the procedure), 2nd visit, 3rd visit, and at least 3 months post-procedure. * Patients who underwent procedures for lesions in a single or adjacent two segments. Exclusion Criteria: * Patients who underwent surgical treatment within one month after the procedure due to progressive neurological deficits. * Patients with severe systemic diseases (e.g., cancer, severe immunosuppressive disorders) that may affect pain assessment. * Patients with severe systemic diseases (e.g., cancer, severe immunosuppressive disorders) that may affect pain assessment.

Primary outcome measure(s)

  • The difference in pain change — baseline, 1 month, 2 month, 3 month
    the difference in pain change, assessed using the visual analogue scale (VAS), between patients who underwent US-CSNRB and those who underwent FL-CTFEB

Trial sites (1)

FacilityCityRegionStatus
Pusan National University Yangsan Hospital Yangsan Gyeongsangnam-do

More Pusan National University Yangsan Hospital trials in South Korea

HB05P on Muscle Health Recruiting
Cardiovascular Autonomic Function After Resistance Training Starting soon
The Study to Evaluate the Safety and Efficacy of the Onyx Family Recruiting
Electromagnetic High-Frequency Chest Wall Oscillation on Pulmonary Mucus Clearance in Patients With Impaired Self-Expectoration Recruiting
Comparison of Sevoflurane and Desflurane on ANI in Patients Undergoing General Anesthesia: a Prospective Randomized Controlled Study Starting soon

Other trials for the same condition

Effectiveness and Safety of Korean Medicine Treatment for Cervical Disc Herniation Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07447271 on ClinicalTrials.gov ↗ ← All trials in South Korea